PDGFRB and neoplasm: Moreover, PDGFR has been the target for many newly developed anticancer drugs, some of them with proven efficacy in CRC (i.e. regorafenib)[7] and some that have failed to demonstrate a benefit in patients with this tumor type (i.e. sunitinib, sorafenib)[16,17].